Short Wave What It's Like Taking Alzheimer's Drugs
8 snips
Mar 3, 2025 Jon Hamilton, NPR Science Correspondent, dives into the promising but complex world of newly approved Alzheimer's drugs. He shares personal stories from patients navigating the challenges of the disease. One woman’s experience in a clinical trial sheds light on the emotional toll alongside potential hope. They discuss the drugs' effectiveness, risks, and how they target beta amyloid plaques. The podcast beautifully intertwines science with human experiences, reminding us of the delicate balance between medical advancements and individual journeys.
AI Snips
Chapters
Transcript
Episode notes
New Alzheimer's Drugs Offer Modest Benefit
- Two new Alzheimer's drugs, Leqembi and Casunla, modestly slow cognitive decline.
- They target amyloid plaques, cost over $25,000 yearly, and have side effects like brain swelling.
Sue Bell's Experience with Leqembi
- Sue Bell, an early Leqembi trial participant, initially saw improvements but later declined.
- Her Alzheimer's progressed, leading to the discontinuation of the drug and eventual placement in a care home.
Mayra Solano-Garcia's Experience with Casunla
- Mayra Solano-Garcia, on Casunla, maintains some abilities and volunteers at a memory care unit.
- She sings for residents, acknowledging her potential future with the disease.